Economy/Home · Economy

[Breaking] OliX Signs Joint Research and Base Sequence Transfer Agreement with Hansoh…Total Contract Value Equivalent to 10% or More of Revenue

OliX announced that it has signed a joint research and base sequence transfer agreement with Hansoh. The contract was signed on August 21, 2026. The counterparties are Hansoh Bio LLC of the United States and Hansoh (Shanghai) Healthtech CO., LTD. and Jiangsu Hansoh Pharmaceutical Group Company Limi

Oseong Kwon
Staff Reporter
4 min read
[Breaking] OliX Signs Joint Research and Base Sequence Transfer Agreement with Hansoh…Total Contract Value Equivalent to 10% or More of Revenue
CBC News

OliX announced that it has signed a joint research and base sequence transfer agreement with Hansoh. The contract was signed on August 21, 2026.

The counterparties are Hansoh Bio LLC of the United States and Hansoh (Shanghai) Healthtech CO., LTD. and Jiangsu Hansoh Pharmaceutical Group Company Limited of China.

Contract Details

Under this agreement, Hansoh will use the base sequence for the development, manufacturing, and commercialization of licensed products within the scope of rights owned or managed by OliX. The base sequence refers to oligonucleotide sequences identified in relation to development candidate substances for two targets.

The contract covers the entire world. The contract period lasts until all payment obligations under the agreement expire or are fully fulfilled.

Contract Value

The contract value includes an upfront fee, development and commercialization milestones, sublicense income, and royalties. The specific contract amount and detailed milestone development stages were withheld from disclosure at the counterparty's request for confidentiality.

However, the company stated that the total contract value is equivalent to 10% or more of its consolidated revenue of approximately 14.7 billion won as of the end of 2025. There is no obligation to return any milestones received at each stage, including the upfront payment.

Conditional Contract and Grounds for Termination

This is a conditional contract that takes effect only upon approval by pharmaceutical regulatory authorities. Revenue recognition under the contract may vary depending on the success of clinical trials and product approval. The contract may be terminated if regulatory authorities halt research and development or if product approval fails.

In addition, the contract may be terminated during research and development, approval, or commercialization if the counterparty expresses its intention to terminate. In that case, OliX has no obligation to pay penalties.

The company stated that it will immediately disclose any future changes to the contract or disclosure obligations that may arise.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.